These beneficial effects of FXR on dyslipidemia sparked interest in the use of FXR agonists to treat not only triglyceride contents in the liver (NAFLD) but also dyslipidemia or hypertriglyceridemia; however, a randomized controlled trial assessing 72-week treatment with the FXR agonist obeticholic acid versus placebo in noncirrhotic NASH patients improved liver fibrosis, but total and LDL serum cholesterol was increased, while HDL-C decreased [127]. The gene discussed is NR1H4; the disease is Hepatic fibrosis.